News | July 22, 2007

Accuray’s Xsight Lung Tracking System Gains Clinical Acceptance

July 23, 2007 – The adoption rate for Accuray’s Xsight Lung Tracking System, a system designed for the noninvasive treatment of lung tumors, is exceeding 97 percent, the company announced. Xsight Lung is designed for use with the CyberKnife Robotic Radiosurgery System.

"The CyberKnife System with Xsight Lung Tracking allows us to break down the barriers to lung cancer treatment. We are now able to give new hope to patients — such as the elderly and those considered medically or surgically inoperable — who previously would have had no other option," said James Schwade, M.D., executive director of the CyberKnife Centers of Miami and Palm Beach.

According to the company, by working seamlessly with Accuray's CyberKnife System and Synchrony Respiratory Tracking System, Xsight Lung Tracking is the only system that uses the body's soft tissue to directly track targets with radiosurgical accuracy. It delivers highly specialized soft tissue tracking by using the actual image intensity of the lung tumor to target the beam, therefore eliminating the need in some cases for implanted fiducial markers.

An additional tool in the treatment of lung cancer is Accuray’s Monte Carlo dose calculation methodology, currently pending FDA 510(k) clearance. Designed to be fast and accurate, the Monte Carlo dose calculation reportedly enables clinicians to more precisely determine, in a matter of minutes, the intensity of radiation to be delivered in areas where tissue densities vary. This is particularly critical with lung cancer, since healthy tissue surrounding tumors is made up of air cavities, which are less dense than the solid tumors.

“Incorporating Monte Carlo dose calculation capabilities into the CyberKnife System will enable clinicians to quickly and precisely plan treatment and accurately determine the resulting radiation delivered to tumors,” said Charlie Ma, Ph.D., director of radiation physics at Fox Chase Cancer Center in Philadelphia.

For more information: www.accuray.com

Related Content

New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA
News | Proton Therapy | June 14, 2019
IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and...
ASTRO Applauds New Prior Authorization Legislation
News | Radiation Therapy | June 07, 2019
The American Society for Radiation Oncology (ASTRO) released a statement applauding Congress’s introduction of...
IBA Dosimetry Launches myQA iON
News | Quality Assurance (QA) | June 07, 2019
IBA (Ion Beam Applications S.A.) announced the launch of myQA iON at the 2019 Particle Therapy Co-Operative Group (...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
Accuray Radixact

Accuray Radixact

Feature | Radiation Therapy | May 29, 2019 | By Jeff Zagoudis
While radiation therapy as a disciplin
Sponsored Content | Case Study | Radiation Therapy | May 29, 2019
The so-called “Grey Tsunami” of baby boomers using healthcare services isn’t taking the Radiation Medicine Program at
Improved Imaging for Prostate Cancer Could Lead to More Effective Treatment

The picture shows that time series signal is extracted from a series of ultrasound frames for classification. Each patch across a number of frames inside the prostate is classified into either cancerous or normal tissue. The image at the lower right corner shows the overall result for those frames. Image courtesy of Pingkun Yan and researchers from NIH, University of British Columbia and Queens University.

News | Ultrasound Imaging | May 28, 2019
Engineers at Rensselaer Polytechnic Institute are working to improve imaging methods in order to make medicine more...